Foundation Medicine, Inc. announced that it has formed a collaboration with Repare Therapeutics to provide prospective genomic profiling to patients in Repare's ongoing Phase I/Ib MYTHIC study (NCT04855656) of lunresertib alone or in combinations in genomically-defined patient populations. The companies are also exploring opportunities to develop FoundationOne®CDx, a tissue-based comprehensive genomic profiling test, as a companion diagnostic for the lunresertib program. Lunresertib is a first-in-class, selective and potent oral small molecule inhibitor of PKMYT1, a cancer target Repare discovered and identified as synthetic lethal with CCNE1 amplification, FBXW7 and PPP2R1A alterations in solid tumors.

Lunresertib is being evaluated alone and in combinations across several studies in the United States, Canada, European Union and United Kingdom. Repare has presented positive initial Phase 1 data, including compelling safety and anti-tumor activity, demonstrating proof of concept for lunresertib alone and in combination with camonsertib, a potential best-in-class ATR inhibitor developed by Repare and in Phase 1/2 development. Using a tissue sample, the U.S. Food and Drug Administration-approved FoundationOneCDx test analyzes more than 300 cancer-related genes for genomic alterations in a patient's tumor.

The test currently has over 35 companion diagnostic indications. Foundation Medicine is the global leader in companion diagnostic approvals with approximately 60% of all U.S. companion diagnostic approvals for next generation sequencing testing.